| SC 13G/A | 2024-02-14 | BIOTECHNOLOGY VALUE FUND L P | Aclaris Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | CITADEL ADVISORS LLC | Aclaris Therapeutics, Inc. | - | 6.1% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | Aclaris Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | Venrock Healthcare Capital Partners II, L.P. | Aclaris Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | Rock Springs Capital Management LP | Aclaris Therapeutics, Inc. | 2,998,495 | 4.2% | EDGAR |
| SC 13G/A | 2024-02-14 | TANG CAPITAL PARTNERS LP | Aclaris Therapeutics, Inc. | 1,753,335 | 2.5% | EDGAR |
| SC 13G | 2024-02-14 | MILLENNIUM MANAGEMENT LLC | Aclaris Therapeutics, Inc. | 3,769,926 | 5.3% | EDGAR |
| SC 13G/A | 2024-02-13 | Foresite Capital Fund IV, L.P. | Aclaris Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G | 2024-02-13 | VANGUARD GROUP INC | Aclaris Therapeutics, Inc. | 4,721,887 | 6.7% | EDGAR |
| SC 13G/A | 2024-02-08 | BML Investment Partners, L.P. | Aclaris Therapeutics, Inc. | 9,395,934 | 13.3% | EDGAR |
| SC 13G/A | 2024-02-01 | MILLENNIUM MANAGEMENT LLC | Aclaris Therapeutics, Inc. | 3,479,361 | 4.9% | EDGAR |
| SC 13G/A | 2024-01-25 | BlackRock Inc. | Aclaris Therapeutics, Inc. | 5,905,872 | 8.3% | EDGAR |
| SC 13G | 2024-01-16 | BML Investment Partners, L.P. | Aclaris Therapeutics, Inc. | 4,500,000 | 6.4% | EDGAR |
| SC 13G/A | 2023-12-11 | WELLINGTON MANAGEMENT GROUP LLP | Aclaris Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G | 2023-12-11 | MILLENNIUM MANAGEMENT LLC | Aclaris Therapeutics, Inc. | 3,588,114 | 5.1% | EDGAR |
| SC 13G | 2023-11-24 | TANG CAPITAL PARTNERS LP | Aclaris Therapeutics, Inc. | 4,338,155 | 6.1% | EDGAR |
| SC 13G | 2023-09-05 | CITADEL ADVISORS LLC | Aclaris Therapeutics, Inc. | - | 4.7% | EDGAR |
| SC 13G/A | 2023-04-10 | WELLINGTON MANAGEMENT GROUP LLP | Aclaris Therapeutics, Inc. | 7,372,601 | 11.0% | EDGAR |
| SC 13G | 2023-03-16 | BIOTECHNOLOGY VALUE FUND L P | Aclaris Therapeutics, Inc. | 1,794,881 | 2.7% | EDGAR |
| SC 13G/A | 2023-02-14 | BIOTECHNOLOGY VALUE FUND L P | Aclaris Therapeutics, Inc. | 1,732,725 | 2.6% | EDGAR |